Study Says Combined Drugs Can Shrink Tumour By 60 Percent In Bowel Cancer

Updated Jul 25, 2024 | 06:09 PM IST

SummaryA new study has found that combining the use of botanciiimab and balstilumab can reduce tumours caused by bowel cancer by 60%, marking the first time a durable response to immunotherapy has been reported in patients suffering from this condition.
close-up-medicine-containers-table

A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

End of Article

After US Loses Measles Elimination Status, Senators Call Out RFK Jr. Over Vaccine Policies

Updated Nov 19, 2026 | 06:00 PM IST

SummaryThe Pan American Health Organization (PAHO) confirmed that the US had lost the status it maintained since 2000. ​The country has recorded more than 5,700 measles cases and 11 deaths. Pennsylvania, the hardest-hit state, has reported its eighth measles-associated death of 2026.
After US Loses Measles Elimination Status, Senators Call Out RFK Jr. Over Vaccine Policies

Credit: AP Photos

After 26 years, the US has lost its measles elimination status, marking a major setback for public health efforts. The resurgence has intensified criticism of Health and Human Services Secretary Robert F. Kennedy Jr. over his vaccine policies and rhetoric.

The Pan American Health Organization (PAHO) confirmed that the US had lost the status it maintained since 2000.

The country has recorded more than 5,700 measles cases and 11 deaths. Pennsylvania, the hardest-hit state, has reported its eighth measles-associated death of 2026.

Measles Infections Among Pregnant Women, Newborns Raise Concern

A CDC-led report identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns.

The actual number may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.

“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.

Decades of MMR vaccination meant many doctors had never encountered measles during their medical careers. However, declining vaccination rates have allowed the disease to spread in under-vaccinated communities.

US Senators Criticise RFK Jr.

Criticism of Kennedy has crossed party lines. Republican Senator Bill Cassidy of Louisiana on Sunday criticised what he called a "series of failures" under Kennedy's leadership at the Department of Health and Human Services.

"This has been a failure. If I were president, I would choose someone else because there needs to be accountability for higher health care costs, more measles deaths, losing elimination status, and no progress on processed foods," Cassidy said on CBS News.

Democratic senators Angela Alsobrooks and Patty Murray have also called for Kennedy's removal.

Alsobrooks (Maryland) condemned the loss of measles elimination status and called Kennedy's tenure a disgrace. She had called for his resignation or dismissal in May 2025. Her resolution of disapproval against Kennedy now has 28 Senate co-sponsors.

Senator Richard Blumenthal (Connecticut) has demanded answers over the alleged suppression of a CDC warning about measles risks during pregnancy, while criticising the administration's vaccine policies.

Murray (Washington) has blamed Trump and Kennedy's leadership for the loss of elimination status and repeatedly called for Kennedy's removal.

Governors Demand Kennedy's Removal

Democratic governors have also blamed Kennedy for the setback. New York Governor Kathy Hochul said the loss of measles elimination status contradicted Kennedy's promise to make America healthy again.

"RFK Jr. promised to 'Make America Healthy Again.' Now America has lost its measles-free status for the first time in 26 years," Hochul said.

"A disgraceful display of incompetence from the nation's highest public health office," she added.

Pennsylvania Governor Josh Shapiro blamed vaccine misinformation and skepticism for the setback. "There is a clear line from the misinformation, vaccine skepticism, and incompetence of RFK Jr. to this devastating news and very real consequences," Shapiro said.

Kentucky Governor Andy Beshear explicitly demanded Kennedy's removal. "This dangerous setback was 100% avoidable and is the result of one person: RFK Jr.," Beshear said. "Remove him now."

An HHS spokesperson rejected the governors' criticism in a statement to Fox News Digital, calling their attacks "baseless" and arguing that declining vaccination rates predated the Trump administration.

The spokesperson said the administration remained focused on expanding vaccine access, closing immunisation gaps and assisting state and local officials with outbreak investigations.

What Has RFK Jr. Said?

Kennedy has vowed to stop measles outbreaks and restore the country's elimination status while continuing to recommend vaccination.

"We will stop measles outbreaks, protect American families, and work to regain U.S. measles elimination status," Kennedy said in a statement.

"I continue to recommend MMR vaccination as the most effective way to prevent measles," he added.

End of Article

Two Surgeons, One Robot: How India's Indigenous System Performed Heart Surgery Without Stopping It

Updated Nov 19, 2026 | 01:16 PM IST

SummaryIndia's indigenous SSI Mantra robotic system enabled two surgeons to perform a five-arm, dual-console beating-heart bypass procedure in a world first. The TECAB surgery was performed at Medanta, Gurugram, without stopping the patient's heart or using a heart-lung machine.
Two Surgeons, One Robot: How India's Indigenous System Performed Heart Surgery Without Stopping It

Credit: iStock

In a world first, India's indigenous SSI Mantra Surgical Robotic System enabled two surgeons to perform a robotic beating-heart bypass procedure using a dual-console setup, according to SS Innovations.

The five-arm robotic system was used for a Totally Endoscopic Coronary Artery Bypass (TECAB) procedure by two surgeons from Medanta Hospital, Gurugram. The surgeons operated through separate control consoles while the patient's heart continued beating, without the use of a heart-lung machine.

They worked in synchrony using all five robotic arms. A heart stabilization system helped steady the target area during the procedure.

“The successful completion of this highly complex beating-heart TECAB procedure demonstrates how robotic surgery can make advanced cardiac interventions less invasive for patients. It is a proud moment for our team and an important step forward for cardiac surgery in India,” said Dr. Naresh Trehan, Chairman and Managing Director, Medanta.

What Makes Dual-Console Robotic Surgery Different?

Also read: Robotics Set to Transform Every Medical Specialty, From Diagnostics to Therapy in India: Jitendra Singh

Unlike conventional robotic cardiac procedures that typically use a single console, a dual-console configuration allows two surgeons to control the robotic system simultaneously. This can improve coordination during complex procedures.

The five-arm configuration allows multiple robotic instruments to be deployed at the same time. It also allows the second surgeon to gain hands-on experience during complex procedures, making the setup potentially useful for surgical training.

How Does Beating-Heart TECAB Surgery Work?

Totally Endoscopic Coronary Artery Bypass, or TECAB, is a minimally invasive form of bypass surgery performed through small incisions, without opening the chest through a conventional sternotomy.

In the beating-heart approach, surgeons perform the bypass while the heart continues beating, without stopping it or using a heart-lung machine. A stabilization system keeps the area being operated on steady.

Robotic cardiac surgery also avoids the extensive chest incision involved in conventional open-heart procedures.

The patient's recovery progress over 15 days offers an initial reference point for assessing the outcome. However, longer-term follow-up and clinical data would be needed to establish the broader benefits of this approach.

Dr. Nitin Kumar Rajput, Associate Director of Robotic and Minimally Invasive Cardiac Surgery at Medanta, said performing a complex beating-heart bypass using five robotic arms and two control consoles required precision, coordination and close collaboration between the surgeons.

“The patient's recovery following surgery was encouraging and reinforces the potential of minimally invasive techniques in advancing cardiac care,” he said.

Read More: Surgeon In Gurugram, Patient In Hyderabad: Could Robotic Telesurgery Bring Specialists To Smaller Cities?

What Is The SSI Mantra Surgical Robotic System?

The SSI Mantra is a modular surgical robotic system that can be configured with three to five arms. It features an ergonomic, open-faced Surgeon Command Centre, a 32-inch 3D 4K monitor and a 23-inch touchscreen for patient information.

The system also offers a real-time virtual view of the robotic arms and allows 3D models generated from diagnostic imaging to be superimposed.

Dr. Sudhir Srivastava, Founder, Chairman and CEO of SS Innovations International, Inc., said the procedure demonstrated the SSI Mantra system's potential in minimally invasive cardiac surgery and marked a major milestone for India's surgical robotics sector.

End of Article

India Proposes Tighter Antimicrobial Drug Regulation To Combat AMR: What It Means

Updated Nov 19, 2026 | 12:27 PM IST

SummaryThe proposed draft would require antimicrobial manufacturers to obtain central approval before seeking state manufacturing licences. The Ministry has also proposed separate licences for the wholesale sale of bulk drugs.
India Proposes Tighter Antimicrobial Drug Regulation To Combat AMR: What It Means

Credit: iStock

Amid rising antimicrobial resistance (AMR) worldwide, the Union Ministry of Health and Family Welfare has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobials under central regulatory oversight.

The amendment seeks to include ‘antimicrobials’ in the definition of ‘New Drug’ under Rule 2(1)(w)(v). Manufacturers would need central approval before applying for a manufacturing licence from state authorities.

"The proposal is intended to serve as an additional regulatory safeguard against antimicrobial resistance (AMR) by strengthening oversight of antimicrobial products and ensuring appropriate scrutiny of their quality, safety and efficacy before the grant of new manufacturing licences," the Ministry said.

AMR occurs when bacteria, viruses, fungi and parasites evolve and no longer respond to medicines designed to treat infections. This makes infections harder to treat, increases the risk of severe illness and death, and can complicate medical procedures such as surgery and cancer treatment.

Addressing the World Antimicrobial Resistance (AMR) Awareness Week 2026, Union Health Secretary Punya Salila Srivastava described AMR as one of the most serious public health challenges. She warned that misuse and overuse of antimicrobials could make even common infections difficult to treat and threaten decades of medical progress.

Also read: Antimicrobial Resistance Could Contribute To 39 Million Deaths By 2050: WHO

What Does The Proposed Amendment Say?

The Ministry proposed the amendment through draft Gazette Notification G.S.R. 983 (E), dated November 6.

Manufacturers would need permission from the Central Licensing Authority (CLA) before applying for a manufacturing licence from the concerned State Licensing Authority (SLA).

Existing manufacturing licences will remain valid, and holders will not need to reapply for permission.

The measure is expected to strengthen central oversight and help ensure the quality, safety and efficacy of antimicrobial products, the Ministry said.

Why Does India Want To Tighten Antimicrobial Regulation?

Read More: ICMR Flags Widespread Antibiotic Resistance Across India: From E. coli To Typhoid, Which Drugs Are Failing?

The proposal follows concerns that antimicrobial manufacturing licences are being granted without adequate regulatory scrutiny, including bioavailability/bioequivalence (BA/BE) and stability studies.

The absence of these assessments may affect product quality, safety and efficacy. Substandard or ineffective antimicrobials can contribute to AMR and pose risks to patient safety.

"The measure is part of the Government's broader efforts to promote the responsible use of antimicrobials, safeguard patient safety and address the growing public health challenge of AMR," the Ministry said.

The amendment remains at the draft stage. The Ministry has invited objections and suggestions from stakeholders and the public before finalisation.

Separate Licences For Bulk Drug Sales

In addition, the Ministry has proposed amendments to the Drugs Rules, 1945, to introduce separate application and licence forms for the wholesale sale of bulk drugs, including active and inactive bulk substances.

Currently, a common licence covers the wholesale sale of both formulations and bulk drugs.

The proposed framework would allow more focused oversight of bulk drug sales and improve accountability in the pharmaceutical supply chain, the Ministry said.

Licences would specify the categories of bulk drugs handled by wholesalers, including those covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. Bulk drug sales would also require the personal supervision of a competent person.

End of Article